Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC Wainwright

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 437.63% from the stock’s previous close.

Several other research firms also recently weighed in on CMPX. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Monday, September 16th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.80.

Compass Therapeutics Trading Up 30.1 %

Shares of NASDAQ:CMPX opened at $1.86 on Wednesday. The firm’s 50 day moving average is $1.57 and its two-hundred day moving average is $1.44. The firm has a market capitalization of $255.92 million, a P/E ratio of -5.03 and a beta of 0.92. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.68.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Analysts predict that Compass Therapeutics will post -0.35 EPS for the current year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its position in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after buying an additional 5,515 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after acquiring an additional 12,315 shares in the last quarter. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics in the 3rd quarter worth $25,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics during the third quarter worth $30,000. Finally, Geode Capital Management LLC raised its position in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares during the period. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.